Pacific Biosciences of California Inc reports results for the quarter ended March 31 - Earnings Summary

• Pacific Biosciences of California Inc PACB.OQ reported a quarterly adjusted loss of $1.44​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -29 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -21 cents to -16 cents per share.

• Revenue fell 4.3% to $37.15 million from a year ago; analysts expected $35.24 million.

• Pacific Biosciences of California Inc shares had risen by 1.7% this quarter and lost 34.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 5.5% in the last three months.​

• In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00

This summary was machine generated from LSEG data May 9 at 12:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)